CRISPR Technologies in Type 2 Diabetes: From Mechanistic Insights to Therapeutic Discovery
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188360 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Shuangshuang Fan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Research Center for Brain-Computer Interface, Key Laboratory of Research and Development of Liaoning Province, College of Life and …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, CRISPR-Cas Systems, Genetic Therapy, Gene Editing. Die Arbeit nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, the 111 Project, the Construction Project of Liaoning Provincial Key Laboratory, China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes (T2D) is a complex metabolic disorder driven by the interplay of genetic susceptibility, β-cell dysfunction, and insulin resistance. Although genome-wide association studies (GWAS) have identified numerous T2D risk loci, translating these genetic findings into biological mechanisms and therapeutic strategies remains challenging. The emergence of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-based technologies has provided powerful tools for precise genome manipulation and functional interrogation of disease-associated genes and genetic variations. This review summarizes the development of CRISPR technologies and highlights their applications in T2D research. We review the application of CRISPR technologies in T2D genetic factor analysis and high-throughput phenotypic screening, with a focus on three key areas: glucose metabolism, lipid metabolism, and pancreatic functionality. We further examine the role of CRISPR in therapeutics that target pancreatic β-cells via gene correction, stress protection, and epigenetic reprogramming. Finally, we briefly discuss the major challenges encountered in the applications of CRISPR technology, including delivery efficiency, off-target effects, safety concerns and ethical considerations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Research Center for Brain-Computer Interface, Key Laboratory of Research and Development of Liaoning Province, College of Life and Health Sciences, Northeastern University, Shenyang 110819, China.
- National Frontiers Science Center for Industrial Intelligence and Systems Optimization, Northeastern University, Shenyang 110819, China.
- Key Laboratory of Data Analytics and Optimization for Smart Industry, Northeastern University, Ministry of Education, Shenyang 110819, China.
ORCID-Profile: Teng Fei
Förderung
- National Key Research and Development Program of China
- the 111 Project
- the Construction Project of Liaoning Provincial Key Laboratory, China
- 111 Project
- Construction Project of Liaoning Provincial Key Laboratory, China
Zitieren
APA
Fan, S., Liang, R., & Fei, T. (2026). CRISPR Technologies in Type 2 Diabetes: From Mechanistic Insights to Therapeutic Discovery. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188360
Vancouver
Fan S, Liang R, Fei T. CRISPR Technologies in Type 2 Diabetes: From Mechanistic Insights to Therapeutic Discovery. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188360
BibTeX
@article{Fan2026,
author = {Fan, Shuangshuang and Liang, Ruipu and Fei, Teng},
title = {CRISPR Technologies in Type 2 Diabetes: From Mechanistic Insights to Therapeutic Discovery},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188360}
}
EUVIMED